WOBURN, Mass., May 15, 2012 /PRNewswire/ -- CutisPharma, Inc. announced the presentation of homogeneity and stability studies for compounded formulations of several "Magic Mouthwash" suspensions using FIRST®- Unit- of- use Prescription Compounding Kits. The poster presentation, by Anisa Gandhi, was at the April 20th American Association of Pharmaceutical Scientists, Northeast Regional Discussion Group (NERDG) Regional Meeting.
"Magic Mouthwash" is commonly prescribed by physicians nationwide. The purpose behind magic mouthwash is to combine various ingredients with different advantages depending on the patient's symptoms. Currently magic mouthwash is extemporaneously prepared or is prepared using FIRST® - Magic Mouthwash Compounding Kits.
The active ingredients used in these FIRST® Magic Mouthwash kits are comparable to those found in the most routinely prescribed "Magic Mouthwash" formulations. These active ingredients are: diphenhydramine hydrochloride, lidocaine hydrochloride, and modified Maalox® in FIRST® - Mouthwash BLM; diphenhydramine hydrochloride, lidocaine hydrochloride, and nystatin in FIRST® -BXN Mouthwash; diphenhydramine hydrochloride, hydrocortisone, and nystatin in FIRST® - Duke's Mouthwash; and diphenhydramine hydrochloride, hydrocortisone, nystatin, and tetracycline in FIRST® - Mary's Mouthwash.
Ms. Gandhi's presentation demonstrated that FIRST® -Mouthwash Kits are uniform in nature for active ingredients. FIRST® Magic Mouthwash Kits are convenient with reliable stability and uniformity data, whereas, the traditional compounding process generally does not have this data available.
FIRST® products save dispensing time, and can be compounded by the pharmacist while the patient waits, increasing customer satisfaction. Using FIRST® Mouthwash kits, the pharmacist can compound a prescription with accuracy faster than those prepared in the conventional way. A single NDC number assigned for the entire kit facilitates the third party reimbursement process, and reduces audit- related adjustments.
CutisPharma now has twenty proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, six Magic Mouthwash kits, three omeprazole suspension kits, and three lansoprazole suspension kits. Several more compounding kits are in the planning stages. The use of FIRST® Unit-of-Use Prescription Compounding Kits facilitates compliance with United States Pharmacopeia (USP) Chapter <795>.
"CutisPharma is committed to maintaining the scientific integrity of the products it develops and commercializes. Studies of this nature also demonstrate the scientific reliability of FIRST® products, as well as confirm their user-friendliness and time-saving benefits" said Dr. Indu Muni, President & CEO of CutisPharma.
CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 10 million currently compounded prescriptions, by offering FIRST® Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Three U.S. patents have been issued to the Company with several additional patents pending.
For more information please visit our website at www.cutispharma.com.
|SOURCE CutisPharma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved